Close Menu

NEW YORK – OncoCyte said after the close of the market on Tuesday that its 2020 Q1 net loss rose about 97 percent year over year, as it reached the cusp of recognizing its first ever revenues.

The liquid biopsy firm's net loss for the three months ended March 31 was $7.7 million, or $0.13 per share, compared to $3.9 million, or $.08 per share, in the same quarter last year, exceeding the consensus Wall Street estimate of a loss of $0.11 per share.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

SARS-CoV-2 vaccine developers are evaluating further vaccine doses as well as modified doses to keep up with new viral variants, according to CNN.

The New York Times reports that a new viral variant of concern has been identified in New York City.

In Nature this week: spatiotemporally resolved map of the human cell cycle, folding single-cell RNA sequencing into cancer drug studies, and more.

According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.